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Abstract
The last three decades have seen a dramatic rise in the implementation of screening programmes
for cancer in industrialised countries. However, in contrast to screening for infectious diseases,
most cancer screening programmes only have the potential to reduce mortality; they cannot lower
the incidence of cancer in a population. In fact, most cancer screening programmes have been
shown to increase the incidence of the disease as a consequence of over-diagnosis. A further
dilemma of cancer screening programmes is that they do not distinguish between healthy people
and those with disease. Rather, they identify a continuum of disease severity. Consequently, many
healthy people who have abnormal screening tests are wrongly diagnosed. Indeed, studies have
demonstrated that for each screening-prevented death from cancer, at least 200 false-positive
results are given. Therefore, screening has the potential to be harmful as well as beneficial. The
psychosocial consequences of false-positive screening results cannot be determined by diagnostic
tests or by other technical means. Instead, patient reported outcome measures must be employed.
To measure the outcomes of screening accurately and comprehensively patient reported outcome
measures have to capture; the nature and extent of the psychosocial consequences and how these
change over time. The outcome measures used must have high content validity and their
psychometric properties should be determined prior to their use in the specific population. In
particular it is important to establish unidimensionality, additivity and item ordering through the
application of Item Response Theory.
Background
The history of medical screening began with that for syph-
ilis and later for tuberculosis. Screening for infectious dis-
eases served a dual purpose; to cure the patient and to
reduce the incidence of the disease in the general popula-
tion [1]. The World Health Organization (WHO) screen-
ing criteria published in 1968 highlighted major concerns
with the occurrence of false-negative screening results; as
people with undetected disease continue to be a source of
infection [2]. The past three decades have seen a dramatic
increase in the implementation of screening programmes
for cancer in industrialised countries. However, in con-
trast to screening for infectious diseases, most cancer
screening programmes only have the potential to reduce
mortality; they cannot lower the incidence of cancer in a
population. In fact, most cancer screening programmes
have been shown to increase the incidence of the disease
as a consequence of over-diagnosis or increase the inci-
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dence of conditions that are characterised as pre-cancers,
dysplasia or atypical cells. [3-7]. It is important to
acknowledge that by far the majority of these are harmless
conditions that will never become invasive cancers [8-12].
Discussion
Cancer screening in a general population does not distin-
guish between healthy people and those with disease.
Rather, it identifies a continuum of disease severity [13].
For example, a recent study by Taupin et al found that
45% of participants screened for colorectal cancer had
either hyperplastic (benign) or adematous (pre-cancer-
ous) polyps which were removed [14]. Most lay people
would probably see the presence of a growth as being
indicative of cancer and its removal as a positive event.
However, as polyps rarely become malignant, their
removal could actually be viewed as over-treatment of a
harmless condition.
Another dilemma with any mass cancer screening pro-
gramme is that screening tests tend to have low predictive
power. Consequently, many healthy people having
abnormal screening tests are wrongly diagnosed (termed
false alarms or "false-positive" results). Indeed, studies
have demonstrated that for each screening-prevented
death from cancer, at least 200 false-positive results are
given [7,15,16]. In the case of mammography screening,
studies have shown that the receipt of a false-positive
result has substantial negative psychosocial consequences
for women. These can persist for up to three years after the
screening procedure [17,18]. Clearly, medical screening
has the potential to be as harmful as it is beneficial [19].
In response to this dilemma the WHO-criteria for screen-
ing have recently been updated. New criteria have been
added concerning ethical aspects of the screening process,
the psychosocial consequences of false-positive screening
results and the need for fully informed consent [20].
The psychosocial consequences of false-positive screening
results cannot be determined by diagnostic tests or by
other technical means. Instead, patient reported outcome
(PRO) measures must be employed. To measure the out-
comes of screening accurately and comprehensively, PRO
measures have to capture:
• the nature of the psychosocial consequences,
￿ the extent of the psychosocial consequences, and
￿ changes in psychosocial consequences over time.
The measures used must have high content validity [21].
This means that they must both cover relevant aspects of
the construct being measured and exclude issues that are
irrelevant. Qualitative research has shown that abnormal
and false-positive cancer screening results have a negative
impact on the following psychosocial domains; anxiety,
fear, mood, behaviour, sleep, sexuality and social func-
tioning [22-26]. Unfortunately, studies reporting on psy-
chosocial aspects of cancer screening have mostly
employed questionnaires that have poor content validity
and/or that have not been validated for this purpose
[14,27-29].
For example, Taupin and colleagues used the SF-36 to
assess the impact of screening for colorectal cancer [14].
There were several flaws in the design of this study which
resulted in an underestimation of the negative conse-
quences of the screening process. First, the authors did not
test the adequacy of the content of the SF-36 for this study
population. It is well established that generic PROs such
as the SF-36 do not necessarily work in a consistent man-
ner across different populations [30] and the instrument's
psychometric properties should have been explored to
justify its use. It is not unreasonable to suppose that the
SF-36 would have low content validity in the setting of
colorectal cancer screening as it does not cover many of
the most important issues related to screening and
because it contains a high number of irrelevant items.
Taupin and colleagues recorded 30 minor and two major
adverse events from the 231 colonoscopies undertaken.
However, it is doubtful whether any of the SF-36 items
would be capable of capturing the thoughts or feelings of
a healthy person who experienced an adverse event.
A major problem with the SF-36 scales is that their items
were selected in order to have high scale consistency.
However, internal consistency does not ensure that a scale
is unidimensional; that is, that all of the items measure a
single underlying construct and so can be added together
to yield a total scale score. Good internal consistency
merely suggests that the items are correlated [31]. Modern
PROs are required to establish unidimensionality (or, in
the case of multidimensional PROs, unidimensionality of
subscales), additivity and item ordering through the
application of Item Response Theory (IRT) [32]. The
Rasch model (an IRT model) provides formal representa-
tion of perfect measurement. Where items are shown to fit
a Rasch model the measure can be shown to posses crite-
rion-related construct validity [33], to be objective [34],
sufficient [35] and, therefore, also reliable [36]. IRT evi-
dence indicates that the SF-36 scales are not unidimen-
sional and that items in the subscales cannot validly be
added together [37].
Participants in the study (who were asymptomatic) were
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￿ gastrointestinal symptoms requiring attendance at a pri-
mary care physician in the previous year,
￿ significant co-morbidity,
￿ a prior diagnosis of cancer,
￿ previous colonic surgery or therapeutic anticoagulation.
Such a group would be expected to have a significantly
better health status than that of an age matched general
population. In fact, the SF-36 failed to show any such dif-
ferences, confirming its lack of sensitivity. Only 37.3% of
those invited chose to participate in the screening study
suggesting that the sample consisted of those who were
most positive about screening. Such people would be
expected to underestimate any negative psychosocial
experiences because of the perceived benefits of the proce-
dure.
Taupin et al only found differences post colonoscopy on
the mood domains of vitality, emotional role limitations
and mental health. However, even for these domains
mean scores only increased between 1.9 and 4.4 points,
well below the 10 to 20 points needed for a clinically
meaningful improvement in health status on the SF-36
subscales [38].
Despite the evidence presented in their paper the authors
concluded that: "Average-risk persons benefit significantly
from colon cancer screening with colonoscopy, by improving in
Mental Health and Vitality domains of Quality of Life". Such
a conclusion is not justified. First, the psychosocial conse-
quences of screening are best investigated in a randomised
design. Secondly, it would be necessary to employ a PRO
with good psychometric and scaling properties. It is essen-
tial that the PRO used has high content validity in order
to capture the psychosocial consequences of screening
accurately. Evidence of the unidimensionality of the col-
lected data should also be reported. Finally, it is pertinent
to ask whether it is ethical to give participants in screening
exercises the impression that they will benefit from the
process itself, given the absence of evidence supporting
this conclusion and the availability of proof that false-
positive results are common and have an adverse effect on
well-being and health status [26,27].
Conclusion
At present it is far from clear that cancer screening in a gen-
eral population is effective. Such screening has the poten-
tial to be as harmful as it is beneficial. It is equally
important to investigate the harms of a screening test as its
benefits. For example, potential reductions in mortality
from cancer need to be contrasted with the psychosocial
consequences of false-positive screening results. When
measuring the adverse effects of screening it is necessary to
employ PRO's that are relevant to the population and that
have good psychometric properties. It is recommended
that the Rasch model should be adopted as the 'gold
standard' for determining the adequacy of a PRO. Only
where the data collected fit the Rasch model can they be
verified as being objective, sufficient and reliable.
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